Part I: Assessment and Diagnostic Strategies for Neurogenic Bladder

References

1. Linsenmeyer TA, Culkin D. APS recommendations 
for the urological evaluation of patients with 
spinal cord injury. J Spinal Cord Med 1999;22(2):139-142.

2. Hicken BL, Putzke JD, Richards JS. Bladder 
management and quality of life after spinal cord injury. Am J Phys Med Rehabil 2001;80:
916-922.

3. Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents 2002;19:592-597.

4. Zorn BH, Montgomery H, Pieper K, et al. 
Urinary incontinence and depression. J Urol 1999;
162:82-84.

5.  Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-465.

6.  Rackley R, Vasavada S, Firoozi F, et al. Neurogenic bladder. Medscape Reference. Updated November 23, 2011. http://emedicine.medscape.com/article/453539-overview#a1. Accessed March 7, 2012.

7. Semins MJ, Chancellor MB. Diagnosis and management of patients with overactive bladder syndrome and abnormal detrusor activity. Nat Clin Pract Urol 2004;1(2):78-84.

8. Kennelly MJ, DeVoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol 2008;10(3):182-191.

9. Kershen RT. Algorithms for the management of overactive bladder. Curr Urol Rep 2009;10(5):352-361.

10. Benevento BT, Sipski ML. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with
spinal cord injury. Phys Ther 2002 Jun;82(6):601-612.

11. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 2000;55(4):490-494.

12. Wyndaele JJ, Kovindha A, Madersbacher H, et al; Committee 10 on Neurogenic Bladder and Bowel of the International Consultation on Incontinence 2008-2009. Neurologic urinary incontinence. Neurourol Urodyn 2010;29(1):159-164.

13. Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010;29:213-240.

14. Smith JH, Berghmans B, Burgio K, et al. Committee 12. Adult conservative management. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 4th International Consultation on Incontinence. Paris, France: Health Publication Ltd; 2009:1025-1120.

15. Wyndaele JJ, Kovindhaa A, Madersbacher H, et al. 
Committee 10. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 4th International Consultation on Incontinence. Paris, France: Health Publication Ltd; 2009:793-960.

16. Yamaguchi O, Nishizawa O, Takeda M, et al; Neurogenic Bladder Society. Clinical guidelines for overactive bladder. Int J Urol 2009;16(2):126-142.

17. Newman DK, Willson MM. Review of intermittent catheterization and current best practices. Urol Nurs 2011;31:12-28.

18. Linsenmeyer TA, Bodner DR, Creasey GH, et al. Bladder management for adults with spinal cord injury. A clinical practice guideline for health-care providers. J Spinal Cord Med 2006;29(5):527-573.

19. Cardenas DD, Moore KN, Dannels-McClure A, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM R 2011;3(5):408-417.

20. Singh G, Thomas DG. The female tetraplegic: an admission of urological failure. Br J Urol 1997;79:708-712.

21. Song GW, Fam BA, Lee IY, et al. Management of neurogenic bladder in female spinal cord injury patients. 
J Am Paraplegia Soc 1984;7(1):4-7.

22. Ginsberg DA. Management of the neurogenic bladder in the female patient. Curr Urol Rep 2006;7(5):423-428.

23. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81-88.

24. Stöhrer M, Mürtz G, Kramer G, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity—results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007;51(1):235-242. 

25. Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006;25(5):441-445.

26. Van Kerrebroeck PE, Amarenco G, Thüroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17(5):499-512.

27. Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J Urol 2009;182(3):1062-1067. 

28. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54(4):740-763.

29. Cole AT, Fried FA. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol 1972;107(1):44-45.

30. Mohfouz W, Corcos J. Management of detrusor external sphincter dyssynergia in neurogenic bladder. Eur J Phys Rehabil Med 2011;67:639-650.

31. Schurch B, Stöhrer M, Kramer G, et al. 
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-697. 

32. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200. 

33. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-750.

34. Karsenty G, Reitz A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68(6):1193-1197. 

35. Gamé X, Khan S, Panicker JN, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU Int 2011;107:1786-1792.

36. Seoane-Rodríguez S, Sánchez R-Losada J, Montoto-Marqués A, et al. Long-term follow-up study of intraurethral stents in spinal cord injured patients with detrusor-sphincter dyssynergia. Spinal Cord 2007;45:621-626. 

37. Tan HJ, Stoffel J, Daignault S, et al. Ileovesicostomy for adults with neurogenic bladders: complications and potential risk factors for adverse outcomes. Neurourol Urodyn 2008;27:238-243.


From the May 01, 2012 Issue of Renal and Urology News